Company Directory / Pharmaceuticals
Public · NASDAQ:NVAXFor profitPharmaceuticalsGaithersburg, Maryland, United States
Novavax
Novavax is a biotechnology company that focuses on the discovery and development of innovative vaccines for various infectious diseases.
- Founded
- 1987 39 years ago
- Staff
- 1001-5000 1,099 on LinkedIn
- Followers
- 74k on LinkedIn
- Funding
- $2.7B as listed, USD
We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats, our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines
Set against six million companies
Size
1001-5000 people: larger than 97% of companies with a size listed. 1,099 people list it on LinkedIn.
Age
39 years old.
Reach
Website ranked #423,570 in the world for traffic, about 84k visits a month. 74,294 followers on LinkedIn.
What it does
BiotechnologyHealth CarePharmaceuticalr&dbusiness partnershipsnanoparticle protein-based technologymatrix-madjuvantvaccines
Funding, as listed
$2.7B raised in total
- Rounds10
- LatestPost ipo equity, Aug 2023
- Latest amountUSD 85,000,000
- Investors6, 4 leading
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Every detail we hold
Everything the source datasets list about Novavax, field by field. Contact details are held but never shown.
The company
- Name
- Novavax
- Type
- For profit
- Status
- Public · NASDAQ:NVAX
- Founded
- 1987
- Founders
- Bror Morein
- Industry
- Pharmaceuticals
- Categories
- Biotechnology, Health Care, Pharmaceutical
- Specialities
- r&d, business partnerships, nanoparticle protein-based technology, matrix-m, adjuvant, vaccines
Where
- City
- Gaithersburg
- Region
- Maryland
- Country
- United States
- Markets
- Washington DC Metro Area, East Coast, Southern US
Size and reach
- Staff band
- 1001-5000
- People on LinkedIn
- 1,099
- LinkedIn followers
- 74,294
- Web traffic rank
- #423,570
- Monthly web visits
- 83,845
Funding, as listed
- Total
- $2,711,620,000 USD
- Rounds
- 10
- Latest round
- Post ipo equity
- Latest round date
- Aug 2023
- Latest amount
- 85,000,000 USD
- Investors
- 6
- Lead investors
- 4
- Stock listing
- NASDAQ:NVAX
- Listing status
- public
Corporate family
- Acquisitions made
- 2
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
Novavax may be growing as evidenced by several indicators. The company has won a key WHO designation, which could potentially lead to increased adoption and sales of its Covid vaccine. Health Canada's approval of an updated Novavax vaccine to protect against COVID-19 suggests an expansion of its product's market reach. Furthermore, Novavax is targeting growth through strategic vaccine initiatives, indicating an active pursuit of business expansion and development.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Pharmaceuticals in United States.
PCI Pharma ServicesPhiladelphia · 5001-10000 people · 71k followersAAmneal PharmaceuticalsBridgewater · 5001-10000 people · 225k followersssanofi-aventis U.SBridgewater · 10001+ peopleRReata PharmaceuticalsPlano · 251-500 people · 23k followersPPortola PharmaceuticalsSouth San Francisco · 51-100 people · 13k followersCCatalent Pharma SolutionsSomerset · 5001-10000 people · 291k followersFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.